Krukovine Suppresses KRAS-Mutated Lung Cancer Cell Growth and Proliferation by Inhibiting the RAF-ERK Pathway and Inactivating AKT Pathway

Krukovine Suppresses KRAS-Mutated Lung Cancer Cell Growth and Proliferation by Inhibiting the RAF-ERK Pathway and Inactivating AKT Pathway

Oncogenic activation of the KRAS gene via point mutations occurs in 20–30% of patients with non-small cell lung cancer (NSCLC). The RAS-RAF-ERK and RAS-PI3K-AKT pathways are the major hyper-activated downstream pathways in RAS mutation, which promotes the unlimited lifecycle of cancer cells and thei...

Full description

Bibliographic Details
Main Authors: Huanling Lai, Yuwei Wang, Fugang Duan, Ying Li, Zebo Jiang, Lianxiang Luo, Liang Liu, Elaine L. H. Leung, Xiaojun Yao
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-08-01
Series:Frontiers in Pharmacology
Subjects:
krukovine
KRAS
non-small cell lung cancer
natural products
inhibitor
RAF
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.00958/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2018.00958/full

Similar Items